Here, we evaluated anti-tumor activity of CYNK-101 in combination with Avelumab, an anti-PD-L1 antibody, against PD-L1+ lung, breast, and bladder cancer cell lines....Our results demonstrate that CYNK-101 has enhanced Avelumab-mediated ADCC activity against PD-L1+ tumor cell lines, such as lung, breast, and bladder cancers.